<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We reviewed the records and marrow biopsy specimens of 75 patients with leukemic, myelodysplastic, or <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> to determine whether the presence of marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> affected engraftment after allogeneic marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>While 28 control patients without <z:mp ids='MP_0003045'>fibrosis</z:mp> achieved prompt engraftment, two of 32 patients (6%) with mild and five of 15 patients (33%) with severe <z:mp ids='MP_0003045'>fibrosis</z:mp> failed </plain></SENT>
<SENT sid="2" pm="."><plain>The rate of myeloid recovery was significantly slower and the dependence on platelet and red blood cell transfusions was significantly longer in patients with severe <z:mp ids='MP_0003045'>fibrosis</z:mp> than in patients with no <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>A finding of severe marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> should therefore be taken into account when evaluating the risks and benefits of marrow transplantation </plain></SENT>
</text></document>